

Pantelis Sarafidis, Charles J. Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko,
Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque, Gérard M. London,
Ziad Massy, Petro Ruggenti, Esteban Porrini, Andrzej Wiecek, Carmine Zoccali,
Francesca Mallamaci and Mads Hornum

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA, *Nephrology Dialysis Transplantation* 2019; gfy407. doi: 10.1093/ndt/gfy407

In the original article, the words 'micro- or microalbuminuria' should have read 'micro- or macroalbuminuria' in the top boxes of Figures 4 and 5.

doi: 10.1093/ndt/gfz137
Advance Access publication 9 August 2019